Incorrect volume of intravenous fluid therapy either too much or too little can significantly cause patient morbidity and mortality¹. With effective hemodynamic measurement and management, patient clinical outcomes can be optimized across the continuum of care.
IV-fluid responsiveness is a major component in the management of septic shock, trauma events and even Enhanced Recovery After Surgery (ERAS), which is showing improved clinical outcomes for patients. That’s why the demand for noninvasive hemodynamic monitoring such as Startling SV has rapidly grown.²
“The FDA-cleared and CE-marked CHEETAH hemodynamic monitoring systems are uniquely designed and strongly positioned as the solution for completely noninvasive and continuous IV-fluid assessment in the operating room or a critical care setting,” said Chris Hutchison, President and CEO of Cheetah Medical.
Starling™ Sv is a noninvasive hemodynamic monitoring system that provides real-time, continuous information on Cardiac Index, Cardiac Output, Stroke Volume Index, Stroke Volume, Total Peripheral Resistance and other important parameters for efficient real-time clinical decision-making and optimized patient outcomes. Dynamic IV fluid-assessment using the newly introduced Starling™ SV and the benchmark CHEETAH NICOM™ systems noninvasively provides real-time data whether a patient will be helped or potentially harmed by additional IV fluids.
“No matter the site of care or the clinical challenge, effective hemodynamic measurement and management is integral to achieving an optimal clinical outcome,” said Douglas Hansell, M.D., Chief Physician Executive for Cheetah Medical.“Approximately 50 percent of hospitalized patients are at risk of hemodynamic overload³ and the only way for obtaining real-time hemodynamic measurements were invasive procedures with level of risks involved Until the introduction of CHEETAH NICOM™. Now, with the Starling SV or CHEETAH NICOM, the clinicians have all of the important parameters continuously available anytime to monitor the patient’s Clinical status and the responsiveness of IV fluids so treatment can modified accordingly to improve the patient clinical outcome.”
The Starling SV system uses bioreactance technology to take measurements continuously and accurately requiring only four easy sensor placements. The technology has been proven to be more accurate and faster compared to invasive technologies such as Pulmonary Artery Catheter and esophageal doppler. The noninvasive Starling SV system has sensitivity of 94% and specificity of 100% predicting IV-fluids responsiveness similarly to invasive esophageal Doppler and other invasive modalities in critical care cases.5,6 The technology also allows clinicians to monitor in real-time the change in cardiac stroke volume which may assist in reducing hospital length of stay (LOS)7 .
Starling™ SV Benefits Summarized:
100% noninvasive, easy to use, with no patient discomfort.
Eliminates risk of infection and vascular damage associated with older, invasive technologies requiring arterial or central lines.
Independently validated against pulmonary artery catheter.
Accuracy not affected by vasopressors, inotropes, and shock states.
EMR-compatible, with the ability to establish a time-stamped patient record for documentation.
Provides continuous information on Cardiac Index, Cardiac Output, StrokeVolume Index, Stroke Volume, Total Peripheral Resistance, and other vitally important parameters.
1Andrew K Hilton, Vincent A Pellegrino and Carlos D Scheinkestel. Avoiding common problems associated with intravenous fluid therapy. Med J Aust 2008; 189 (9): 509-513.
2 Marik PE, et al. Hemodynamic parameters to guide fluid therapy. Ann of Intensive Care 2011; 1:1.
5 Cecconi M, Backer DD, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. 2014
6 Marik PE, et al. Chest, 2013.